8.7 C
London
Friday, March 29, 2024
HomeFinTechTelix Pharmaceuticals: Receives approval from U.S. FDA for ZIRCON study

Telix Pharmaceuticals: Receives approval from U.S. FDA for ZIRCON study

Date:

Telix Pharmaceuticals: Receives approval from U.S FDA for ZIRCON study

  • Telix Pharmaceuticals (TLX) has received approval from the U.S. Food and Drug Administration for the ZIRCON study
  • The ZIRCON study is an international Phase III study to evaluate the utility of Telix’s product which treats clear cell renal cancer
  • Receipt of an Investigational New Drug notice of allowance will enable patient recruitment to begin in the U.S. in 30 days
  • In 2018 more than 400,000 people worldwide were diagnosed with kidney cancer and more than 175,000 died from it
  • Then the trial expected to complete enrolment in the mid-year
  • Telix has also ended the day up 3.45 per cent with shares trading for $1.50 each

Related stories

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

spot_img